Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Sergio Muñoz-Martínez¹, Victor Sapena¹, Alejandro Forner¹, Jean-Charles Nault^{2

3

4}, Gonzalo Sapisochin⁵, Lorenza Rimassa^{6

7}, Bruno Sangro⁸, Jordi Bruix¹, Marco Sanduzzi-Zamparelli¹, Wacław Hołówko⁹, Mohamed El Kassas¹⁰, Tudor Mocan¹¹, Mohamed Bouattour¹², Philippe Merle¹³, Frederik J H Hoogwater¹⁴, Saleh A Alqahtani¹⁵, Helen L Reeves¹⁶, David J Pinato¹⁷, Emmanouil Giorgakis¹⁸, Tim Meyer¹⁹, Gerda Elisabeth Villadsen²⁰, Henning Wege²¹, Massimiliano Salati²², Beatriz Mínguez²³, Giovan Giuseppe Di Costanzo²⁴, Christoph Roderburg²⁵, Frank Tacke²⁵, María Varela²⁶, Peter R Galle²⁷, Mario Reis Alvares-da-Silva²⁸, Jörg Trojan²⁹, John Bridgewater³⁰, Giuseppe Cabibbo³¹, Christian Toso³², Anja Lachenmayer³³, Andrea Casadei-Gardini³⁴, Hidenori Toyoda³⁵, Tom Lüdde³⁶, Rosanna Villani³⁷, Ana María Matilla Peña³⁸, Cassia Regina Guedes Leal³⁹, Monica Ronzoni⁴⁰, Manuel Delgado⁴¹, Christie Perelló⁴², Sonia Pascual⁴³, José Luis Lledó⁴⁴, Josepmaria Argemi⁴⁵, Bristi Basu^{46

47}, Leonardo da Fonseca⁴⁸, Juan Acevedo⁴⁹, Alexander R Siebenhüner⁵⁰, Chiara Braconi⁵¹, Brandon M Meyers⁵², Alessandro Granito⁵³, Margarita Sala⁵⁴, Carlos Rodríguez-Lope⁵⁵, Lorraine Blaise^{2

3

4}, Manuel Romero-Gómez⁵⁶, Federico Piñero⁵⁷, Dhanny Gomez⁵⁸, Vivianne Mello⁵⁹, Rogerio Camargo Pinheiro Alves⁶⁰, Alex França⁶¹, Fernanda Branco⁶², Giovanni Brandi⁶³, Gustavo Pereira⁶⁴, Susanna Coll⁶⁵, Maria Guarino⁶⁶, Carlos Benítez⁶⁷, Maria Margarita Anders⁶⁸, Juan C Bandi⁶⁹, Mercedes Vergara^{70

71

72}, Mariona Calvo⁷³, Markus Peck-Radosavljevic⁷⁴, Ignacio García-Juárez⁷⁵, Vincenzo Cardinale⁷⁶, Mar Lozano⁷⁷, Martina Gambato^{78

79}, Stefano Okolicsanyi⁸⁰, Dalia Morales-Arraez⁸¹, Alessandra Elvevi⁸², Alberto E Muñoz⁸³, Alberto Lué⁸⁴, Massimo Iavarone⁸⁵, Maria Reig¹

Affiliations

¹ BCLC group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
² Service d'hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France.
³ Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris Nord, Paris, France.
⁴ Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, Université Paris, INSERM UMR 1138 Functional Genomics of Solid Tumors Laboratory, Paris, France.
⁵ Abdominal Transplant & HPB Surgical Oncology, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Canada.
⁶ Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
⁷ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁸ Unidad de Hepatología, Clínica Universidad de Navarra, IDISNA, CIBERehd, Pamplona, Spain.
⁹ Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
¹⁰ Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
¹¹ 3rd Medical Department, 'Octavian Fodor' Institute for Gastroenterology and Hepatology, Cluj-Napoca, Romania.
¹² AP-HP, Hôpital Beaujon, Department of Digestive Oncology, Clichy, France.
¹³ Department of Hepatology, Groupement Hospitalier Lyon Nord, Lyon, France.
¹⁴ Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, the Netherlands.
¹⁵ Department of Liver Transplant, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
¹⁶ Liver Unit, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
¹⁷ Department of Surgery and Cancer, Imperial College London, London, UK.
¹⁸ Division of Transplantation, Department of Surgery, UAMS Medical Center, Winthrop P. Rockefeller Cancer Institute, Little Rock, AK, USA.
¹⁹ Department of Oncology, Royal Free Hospital, London, UK.
²⁰ Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
²¹ Department of Internal Medicine, Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
²² Department of Clinical and Experimental Medicine, University Hospital of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy.
²³ Liver Unit, Hospital Universitari Vall d'Hebron, Liver Diseases Research Group, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus. Universitat Autònoma de Barcelona, Barcelona, Spain.
²⁴ Liver Unit, A Cardarelli Hospital, Naples, Italy.
²⁵ Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, Berlin, Germany.
²⁶ Department of Gastroenterology and Hepatology. Hospital Universitario Central de Asturias, IUOPA, ISPA, Universidad de Oviedo, Oviedo, Spain.
²⁷ I. Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany.
²⁸ GI/Liver Unit, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
²⁹ Medical Clinic 1, Goethe University Hospital, Frankfurt, Germany.
³⁰ Department of Oncology, University College of London, London, UK.
³¹ Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.
³² Department of Surgery, Geneva University Hospitals, Geneva, Switzerland.
³³ Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
³⁴ Department of Medical Oncology, University of Modena and Reggio Emilia, Modena, Italy.
³⁵ Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
³⁶ Clinic for Gastroenterology, Hepatology and Infectious Disease, University Hospital Düsseldorf, Düsseldorf, Germany.
³⁷ Liver Unit, Department of Surgical and Medical Sciences, University of Foggia, Foggia, Italy.
³⁸ Gastroenterology and Hepatology, H.G.U. Gregorio Marañon, CIBERehd, Madrid, Spain.
³⁹ Gastroenterology, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil.
⁴⁰ Medical Oncology Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
⁴¹ Department of Digestive Disease, University Hospital La Coruña, La Coruña, Spain.
⁴² Department of Gastroenterology and Hepatology, University Hospital Puerta de Hierro, Majadahonda, Spain.
⁴³ Liver Unit, HGU Alicante, CIBERehd, Alicante, Spain.
⁴⁴ Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
⁴⁵ Internal Medicine - Liver Unit, Clinica Universidad de Navarra, Pamplona, Spain.
⁴⁶ Department of Oncology, University of Cambridge, Cambridge, UK.
⁴⁷ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁴⁸ Department of Clinical Oncology, Sao Paulo Clinicas Liver Cancer group, Insitituto do Cancer do Estado de São Paulo, University of São Paulo, San Paulo, Brazil.
⁴⁹ South West Liver Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK.
⁵⁰ Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
⁵¹ Department of Medical Oncology, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
⁵² Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
⁵³ Division of Internal Medicine, Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
⁵⁴ Department of Gastroenterology, Hepatology Unit, Hospital Doctor Josep Trueta, CIBERehd, Girona, Spain.
⁵⁵ Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
⁵⁶ SeLiver group, UGC de Enfermedades Digestivas, Instituto de Biomedicina de Sevilla, Hospital Virgen del Rocío, CIBERehd, Seville, Spain.
⁵⁷ Liver Unit, Hospital Universitario Austral, Pilar, Argentina.
⁵⁸ HPB Surgery and Hepatology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
⁵⁹ Department of Oncology, AMO Clinic, Salvador, Brazil.
⁶⁰ Department of Gastroenterology, Hospital do Servidor Publico Estadual de São Paulo, San Paulo, Brazil.
⁶¹ Department of Medicine, Federal University of Sergipe, Aracaju, Brazil.
⁶² Department of Hepatology, CliniOnco, Porto Alegre, Brazil.
⁶³ Division of Oncology - Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna, Italy.
⁶⁴ Gastroenterology and Hepatology Unit, Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil.
⁶⁵ Hepatology Section, Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
⁶⁶ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
⁶⁷ Department of Gastroenterology, Pontificia Universidad Católica de Chile, Santiago, Chile.
⁶⁸ Sección Hepatología, Hospital Aleman, Buenos Aires, Argentina.
⁶⁹ Department of Hepatology, Hospital Italiano, Buenos Aires, Argentina.
⁷⁰ Unitat d'Hepatologia, Servei d'Aparell Digestiu, Parc Taulí Sabadell Hospital Universitari, Institut d'Investigació i Innovació I3PT, Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.
⁷¹ Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.
⁷² CIBERehd, Instituto Carlos III, Madrid, Spain.
⁷³ Oncología Médica, Institut Català d'Oncologia, L'Hospitalet del Llobregat, Barcelona, Spain.
⁷⁴ Innere Medizin & Gastroenterologie, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria.
⁷⁵ Gastroenterology Department, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico.
⁷⁶ Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy.
⁷⁷ Aparato Digestivo, Hospital Universitario Infanta Leonor, Madrid, Spain.
⁷⁸ Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.
⁷⁹ Multivisceral Transplant Unit, Gastroenterology, Padua University Hospital, Padua, Italy.
⁸⁰ Department of Surgical Disciplines, Gastroenterology and Digestive Endoscopy, Umberto Parini Hospital, Aosta, Italy.
⁸¹ Department of Gastroenterology and Hepatology, Hospital Universitario de Canarias, La Laguna, Spain.
⁸² Division of Gastroenterology and Center for Autoimmune Liver Diseases, San Gerardo Hospital University of Milano-Bicocca School of Medicine, Monza, Italy.
⁸³ Sección Hepatología, Hospital Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina.
⁸⁴ Gastroenterology, Hepatology and Nutrition Unit, San Jorge General Hospital, Huesca, Spain.
⁸⁵ Foundation IRCCS Ca' Granada Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC 'A.M. and A. Migliavacca' Center for Liver Disease, Milan, Italy.

PMID: 33644725
PMCID: PMC7901294
DOI: 10.1016/j.jhepr.2021.100260

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Sergio Muñoz-Martínez et al. JHEP Rep. 2021 Jun.

. 2021 Jun;3(3):100260.

doi: 10.1016/j.jhepr.2021.100260. Epub 2021 Feb 23.

Authors

Affiliations

¹ BCLC group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
² Service d'hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France.
³ Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris Nord, Paris, France.
⁴ Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, Université Paris, INSERM UMR 1138 Functional Genomics of Solid Tumors Laboratory, Paris, France.
⁵ Abdominal Transplant & HPB Surgical Oncology, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Canada.
⁶ Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
⁷ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁸ Unidad de Hepatología, Clínica Universidad de Navarra, IDISNA, CIBERehd, Pamplona, Spain.
⁹ Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
¹⁰ Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
¹¹ 3rd Medical Department, 'Octavian Fodor' Institute for Gastroenterology and Hepatology, Cluj-Napoca, Romania.
¹² AP-HP, Hôpital Beaujon, Department of Digestive Oncology, Clichy, France.
¹³ Department of Hepatology, Groupement Hospitalier Lyon Nord, Lyon, France.
¹⁴ Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, the Netherlands.
¹⁵ Department of Liver Transplant, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
¹⁶ Liver Unit, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
¹⁷ Department of Surgery and Cancer, Imperial College London, London, UK.
¹⁸ Division of Transplantation, Department of Surgery, UAMS Medical Center, Winthrop P. Rockefeller Cancer Institute, Little Rock, AK, USA.
¹⁹ Department of Oncology, Royal Free Hospital, London, UK.
²⁰ Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
²¹ Department of Internal Medicine, Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
²² Department of Clinical and Experimental Medicine, University Hospital of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy.
²³ Liver Unit, Hospital Universitari Vall d'Hebron, Liver Diseases Research Group, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus. Universitat Autònoma de Barcelona, Barcelona, Spain.
²⁴ Liver Unit, A Cardarelli Hospital, Naples, Italy.
²⁵ Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, Berlin, Germany.
²⁶ Department of Gastroenterology and Hepatology. Hospital Universitario Central de Asturias, IUOPA, ISPA, Universidad de Oviedo, Oviedo, Spain.
²⁷ I. Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany.
²⁸ GI/Liver Unit, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
²⁹ Medical Clinic 1, Goethe University Hospital, Frankfurt, Germany.
³⁰ Department of Oncology, University College of London, London, UK.
³¹ Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.
³² Department of Surgery, Geneva University Hospitals, Geneva, Switzerland.
³³ Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
³⁴ Department of Medical Oncology, University of Modena and Reggio Emilia, Modena, Italy.
³⁵ Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
³⁶ Clinic for Gastroenterology, Hepatology and Infectious Disease, University Hospital Düsseldorf, Düsseldorf, Germany.
³⁷ Liver Unit, Department of Surgical and Medical Sciences, University of Foggia, Foggia, Italy.
³⁸ Gastroenterology and Hepatology, H.G.U. Gregorio Marañon, CIBERehd, Madrid, Spain.
³⁹ Gastroenterology, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil.
⁴⁰ Medical Oncology Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
⁴¹ Department of Digestive Disease, University Hospital La Coruña, La Coruña, Spain.
⁴² Department of Gastroenterology and Hepatology, University Hospital Puerta de Hierro, Majadahonda, Spain.
⁴³ Liver Unit, HGU Alicante, CIBERehd, Alicante, Spain.
⁴⁴ Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
⁴⁵ Internal Medicine - Liver Unit, Clinica Universidad de Navarra, Pamplona, Spain.
⁴⁶ Department of Oncology, University of Cambridge, Cambridge, UK.
⁴⁷ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁴⁸ Department of Clinical Oncology, Sao Paulo Clinicas Liver Cancer group, Insitituto do Cancer do Estado de São Paulo, University of São Paulo, San Paulo, Brazil.
⁴⁹ South West Liver Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK.
⁵⁰ Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
⁵¹ Department of Medical Oncology, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
⁵² Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
⁵³ Division of Internal Medicine, Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
⁵⁴ Department of Gastroenterology, Hepatology Unit, Hospital Doctor Josep Trueta, CIBERehd, Girona, Spain.
⁵⁵ Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
⁵⁶ SeLiver group, UGC de Enfermedades Digestivas, Instituto de Biomedicina de Sevilla, Hospital Virgen del Rocío, CIBERehd, Seville, Spain.
⁵⁷ Liver Unit, Hospital Universitario Austral, Pilar, Argentina.
⁵⁸ HPB Surgery and Hepatology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
⁵⁹ Department of Oncology, AMO Clinic, Salvador, Brazil.
⁶⁰ Department of Gastroenterology, Hospital do Servidor Publico Estadual de São Paulo, San Paulo, Brazil.
⁶¹ Department of Medicine, Federal University of Sergipe, Aracaju, Brazil.
⁶² Department of Hepatology, CliniOnco, Porto Alegre, Brazil.
⁶³ Division of Oncology - Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna, Italy.
⁶⁴ Gastroenterology and Hepatology Unit, Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil.
⁶⁵ Hepatology Section, Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
⁶⁶ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
⁶⁷ Department of Gastroenterology, Pontificia Universidad Católica de Chile, Santiago, Chile.
⁶⁸ Sección Hepatología, Hospital Aleman, Buenos Aires, Argentina.
⁶⁹ Department of Hepatology, Hospital Italiano, Buenos Aires, Argentina.
⁷⁰ Unitat d'Hepatologia, Servei d'Aparell Digestiu, Parc Taulí Sabadell Hospital Universitari, Institut d'Investigació i Innovació I3PT, Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.
⁷¹ Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.
⁷² CIBERehd, Instituto Carlos III, Madrid, Spain.
⁷³ Oncología Médica, Institut Català d'Oncologia, L'Hospitalet del Llobregat, Barcelona, Spain.
⁷⁴ Innere Medizin & Gastroenterologie, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria.
⁷⁵ Gastroenterology Department, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico.
⁷⁶ Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy.
⁷⁷ Aparato Digestivo, Hospital Universitario Infanta Leonor, Madrid, Spain.
⁷⁸ Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.
⁷⁹ Multivisceral Transplant Unit, Gastroenterology, Padua University Hospital, Padua, Italy.
⁸⁰ Department of Surgical Disciplines, Gastroenterology and Digestive Endoscopy, Umberto Parini Hospital, Aosta, Italy.
⁸¹ Department of Gastroenterology and Hepatology, Hospital Universitario de Canarias, La Laguna, Spain.
⁸² Division of Gastroenterology and Center for Autoimmune Liver Diseases, San Gerardo Hospital University of Milano-Bicocca School of Medicine, Monza, Italy.
⁸³ Sección Hepatología, Hospital Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina.
⁸⁴ Gastroenterology, Hepatology and Nutrition Unit, San Jorge General Hospital, Huesca, Spain.
⁸⁵ Foundation IRCCS Ca' Granada Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC 'A.M. and A. Migliavacca' Center for Liver Disease, Milan, Italy.

PMID: 33644725
PMCID: PMC7901294
DOI: 10.1016/j.jhepr.2021.100260

Abstract

Background & aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.

Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).

Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.

Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.

Keywords: BCLC, Barcelona Clinic Liver Cancer; CERO-19, Liver Cancer Outcome in the COVID-19-pandemic Project; COVID-19; COVID-19, coronavirus disease 2019; Cholangiocarcinoma; Clinical trials; ENS-CCA, European Network for the Study of Cholangiocarcinoma; HCC, hepatocellular carcinoma; Hepatocellular carcinoma; LC, liver cancer; LT, liver transplantation; Liver cancer; Management; Nurses; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; iCCA, intrahepatic cholangiocarcinoma.

PubMed Disclaimer

Conflict of interest statement

SM.-M.: Speaker fees from Bayer and travel funding from 10.13039/100004326Bayer and 10.13039/501100014382Eisai. V.S.: Travel grants from 10.13039/100004326Bayer. A.F.: Lecture fees from Bayer, Gilead and MSD; consultancy fees from Bayer, AstraZeneca, Roche and Guerbert. J-C.N.: Received research grant from 10.13039/100004326Bayer for Inserm UMR1138. L.R.: Reports receiving consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi; lectures fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi; travel fees from Ipsen; and institutional research funding from Agios, ARMO BioSciences, 10.13039/100004325AstraZeneca, BeiGene, 10.13039/501100003769Eisai, 10.13039/100010544Exelixis, 10.13039/100006591Fibrogen, Incyte, 10.13039/501100014382Ipsen, 10.13039/100004312Lilly, 10.13039/100007054MSD, 10.13039/100004337Roche. B.S.: Reports consultancy fees from Adaptimmune, AstraZeneca, Bayer, BMS, BTG, Eli Lilly, Ipsen, Novartis, Merck, Roche, Sirtex Medical, Terumo; and research grants from 10.13039/100002491BMS and Sirtex Medical. J. Bruix: Consultancy: AbbVie, ArQule, Astra, Basilea, Bayer, BMS, Daiichi Sankyo, GlaxoSmithKline, Gilead, Kowa, Lilly, Medimune, Novartis, Onxeo, Polaris, Quirem, Roche, Sanofi-Aventis, Sirtex, Terumo/Grants: 10.13039/100004326Bayer and 10.13039/501100014382Ipsen. M.S.Z.: Received speaker fees and travel grants from 10.13039/100004326Bayer and 10.13039/100014869BTG, 10.13039/100007054MSD. M.B.: Consultant and Advisory Board for: Bayer Pharma, Ipsen, BMS, Eisai, Roche, AstraZeneca, Sirtex Medical. D.J.P.: Received lecture fees from ViiV Healthcare and Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, and AstraZeneca; received research funding (to institution) from MSD and BMS. T.M.: Consultancy: Eisai, Roche, BTG, Ipsen, Bayer, Adaptimmune. Research funding: Bayer, BTG. H.W.: Served as speaker for Bayer, Eisai, and Ipsen, and as a consultant for Bayer, Eisai, Lilly, BMS, Roche, and Ipsen. B.M.: Consultancy: Bayer-Shering Pharma /Speaker fees: Eisai, MSDG. C. Consultancy fees from Bayer, Ipsen. P.R.G.: Bayer, BMS, MSD, AstraZeneca, Adaptimmune, Sirtex, Lilly Ipsen, Roche, Eisai. M.R.A.S.: Has received Research grants, advisory board or speaker fees for 10.13039/100006483AbbVie, 10.13039/100004326Bayer, Biolab, Intercept, 10.13039/501100014382Ipsen, 10.13039/100008799Gilead, 10.13039/100009947MSD, 10.13039/100004336Novartis, and 10.13039/100004337Roche. J.T.: Has received research grants from 10.13039/100004337Roche and 10.13039/501100014382Ipsen. He has received speaker and consulting honoraria from AstraZeneca, Amgen, Bayer Healthcare, Bristol Myers-Squibb, Eisai, Ipsen, Merck Serono, Merck Sharp & Dome, Lilly Imclone, and Roche. J. Bridgewater: Consultancy Bayer, BMS, Incyte, Taiho, Roche, MSD and Merck Serono. Research funding from Incyte. G.C.: Consultancy fees from Bayer, Ipsen. A.L.: Consultancy CAScination, Advisory Board Neuwave and Histosonics. H.T.: Speaker fees from AbbVie, Gilead, MSD, and Bayer. R.V.: Research grant from 10.13039/100006483Abbvie. A.M.M.P.: Speaker honorarium from Bayer, BMS, Boston Scientific and EISAI. Consulting honorarium from Bayer, AstraZeneca and EISAI. Advisory honorarium from Bayer, AstraZeneca and EISAI. Grants from 10.13039/100004326Bayer and 10.13039/100008497Boston Scientific. M.D.: Has received consulting and training fees from Bayer and Eisai. B.B.: Reports Consultancy for GenMab (paid to Institution); Advisory Boards for Roche (paid to Institution), Eisai Europe Limited (paid to Institution), research grant from 10.13039/100006436Celgene Ltd (paid to Institution), Speakers Bureau for Eisai Europe Limited (paid to Institution), Travel and registration for Congress from Bayer. L.d.F.: Lectures fees from BMS, Roche and Bayer. B.M.M.: Advisory/Speaker: Amgen, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Merck, Roche, Sanoffi Genzyme, Taiho. Expert Testimony: Eisai, Roche. Travel: Eisai, Merck. Research: Sillajen (Individual); AstraZeneca, H3/Eisai, Galera, GSK, Exelixis (Institution). M.S.: Travel/ accommodation/meeting expenses: Bayer. Eisai. Speaker fees: Bayer. C.R.L.: Travel grants from 10.13039/100004326Bayer. M.R-G.: Reports grants from Intercept, grants from 10.13039/100005564Gilead-Sciences, personal fees from Shionogi, personal fees from Alfa-Wasserman, personal fees from Prosciento, personal fees from Kaleido, personal fees from Novonrdisk, personal fees from MSD, personal fees from BMS, personal fees from Allergan, personal fees from Boehriger-Ingelheim, personal fees from Zydus, personal fees from Intercept Pharma, personal fees from Gilead-Sciences, outside the submitted work. F.P.: Disclosures: Received speaker honoraria from Bayer, Roche, LKM-Biotoscana, RAFFO. Research Grants from INC Argentinean 10.13039/100013137National Institute of Corrections, 10.13039/100004337Roche. V.M.: Lectures sponsored by Bayer. G.B.: Advisory board Eli-Lilly and Incyte. M. Vergara: Travel grants from 10.13039/100004326Bayer, 10.13039/100008799Gilead, 10.13039/100009947MSD and 10.13039/100006483Abbvie. Lectures sponsored by Gilead, Abbvie, Intercept, and MSD. M.L.: Lectures and educational presentations: Abbvie. Travel/accommodation, meeting expenses covered by Bayer, Gilead, Abbvie. M.I.: Received speaker honoraria from Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, EISAI, and was consultant for BTG-Boston Scientific, Bayer, and Guerbet. M.R.: Consultancy: Bayer-Schering Pharma, BMS, Roche, Ipsen, AstraZeneca, Lilly, BTG/Paid conferences: Bayer-Schering Pharma, BMS, Gilead, Lilly/Research Grants: 10.13039/100004326Bayer-Schering Pharma, 10.13039/501100014382Ipsen. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

**Fig. 1**
Areas in which pre-pandemic clinical practices were modified expressed as percentages. Grey bars represent the percentage of centres that had to modify their clinical practice in the main areas mentioned in the left of the figure.

**Fig. 2**
Criteria used to maintain pre-defined schedules of diagnostic and staging procedures. Grey bars represent the percentage of centres that used each of the criteria mentioned in the left of the figure to maintain pre-defined schedules of diagnostic and staging procedures.

**Fig. 3**
Criteria used to maintain the therapy schedule unaltered. Grey bars represent the percentage of centres that used each of the criteria mentioned in the left of the figure to maintain their therapy schedule unaltered.

See this image and copyright information in PMC

References

1. Pinato D.J., Zambelli A., Aguilar-Company J., Bower M., Sng C.C.T., Salazar R. Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer. Canc Discov. 2020;10:1465–1474. - PMC - PubMed
1. Pinato D.J., Lee A.J.X., Biello F., Seguí E., Aguilar-Company J., Carbó A. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe. Cancers (Basel) 2020;12:1–13. - PMC - PubMed
1. Marjot T., Moon A.M., Cook J.A., Abd-Elsalam S., Aloman C., Armstrong M.J. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567–577. - PMC - PubMed
1. Iavarone M., D’Ambrosio R., Soria A., Triolo M., Pugliese N., Del Poggio P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73:1063–1071. - PMC - PubMed
1. Amaddeo G., Brustia R., Allaire M., Lequoy M., Hollande C., Regnault H. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. JHEP Rep. 2021 doi: 10.1016/j.jhepr.2020.100199. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Affiliations

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous